The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Hims & Hers, which markets compounded versions of semaglutide through its telehealth platform, released clinical data shortly after Novo’s statement. The data showed that users of its compounded GLP-1 ...